Document is current
Any future updates will be listed below
-
Authors
Wong-Campos, J. David https://orcid.org/0000-0002-8219-2944
Park, Pojeong https://orcid.org/0000-0002-5574-6104
Lee, Byung Hun https://orcid.org/0000-0002-0001-4846
Davis, Hunter C.
Qi, Yitong
Tian, He https://orcid.org/0000-0003-3282-7275
Itkis, Daniel G.
Kim, Doyeon https://orcid.org/0009-0001-8370-3160
Grimm, Jonathan B. https://orcid.org/0000-0003-0331-4200
Plutkis, Sarah E. https://orcid.org/0009-0003-1822-0466
Lavis, Luke D. https://orcid.org/0000-0002-0789-6343
Cohen, Adam E. https://orcid.org/0000-0002-8699-2404
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01-NS126043)
U.S. Department of Health & Human Services | National Institutes of Health (R01-NS133755)
U.S. Department of Health & Human Services | National Institutes of Health (R01-MH117042)
United States Department of Defense | United States Navy | Office of Naval Research (N00014-18-1-2859)
Life Sciences Research Foundation
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 28 April 2025
Accepted: 8 May 2026
First Online: 19 June 2026
Competing interests
: A.E.C. is a consultant to Quiver Biosciences and Exin Therapeutics and is a founder of Luminos LLC. L.D.L. is a scientific cofounder, shareholder and consultant of Eikon Therapeutics. US patent 9,933,417 describing azetidine-containing fluorophores and variant compositions (with L.D.L. as inventor) is assigned to the Howard Hughes Medical Institute. The other authors declare no competing interests.
